1,720,992 research outputs found
Supplemental material for Therapeutic hypothermia for acute ischaemic stroke. Results of a European multicentre, randomised, phase III clinical trial
No full textSupplemental Material for Therapeutic hypothermia for acute ischaemic stroke. Results of a European multicentre, randomised, phase III clinical trial by H Bart van der Worp, Malcolm R Macleod, Philip MW Bath, Raj Bathula, Hanne Christensen, Bridget Colam, Charlotte Cordonnier, Jacques Demotes-Mainard, Isabelle Durand-Zaleski, Christian Gluud, Janus Christian Jakobsen, Bernd Kallmünzer, Rainer Kollmar, Derk W Krieger, Kennedy R Lees, Dominik Michalski, Carlos Molina, Joan Montaner, Risto O Roine, Jesper Petersson, Richard Perry, Nikola Sprigg, Dimitre Staykov, Istvan Szabo, Geert Vanhooren, Joanna M Wardlaw, Per Winkel, Stefan Schwab and the EuroHYP-1 investigators in European Stroke Journal</p
Towards a European Clinical Research Infrastructures Network: The ECRIN Programme
No full textOn the basis of the interconnection of national networks of clinical research centres (CRCs) and clinical trials units (CTUs), the European Clinical Research Infrastructures Network (ECRIN) programme aims to develop an infrastructure allowing for bottom-up harmonisation of the support and training for, and practice of, clinical research, and to provide public sponsors for biotechnology small and medium-sized companies (SMEs) with support for translational research and multicentre clinical studies in Europe. This will be achieved through an application to the next FP6 "Integrated Infrastructure Initiatives" call. However, prior work is required to improve the reciprocal knowledge of partners in the ECRIN consortium and, as a first step, country-specific workshops will be organised by national networks in order to address the organisation of CRC/CTUs and national networks, and their interaction with the national environment of clinical research; this will enable in-depth discussion addressing the bottlenecks hampering transnational studies
Public-Private Partnership Models in France and in Europe
No full textThe workshop entitled “Public-Private partnerships models in Europe
– comparison between France and European countries” brought together
representatives of academia and industry, of national or European health
research programs, of regional or national public-private partnership (PPP)
initiatives, and of biotechnology with the following objectives:
sharing a common vision on the needs, expectations and challenges of public-private partnership,
based on the analysis of actual and original cases, and of new initiatives on public-private partnership,
drawing conclusions and identifying key success factors,
identifying trails for progress and drawing recommendations.
The major event in this field is a European public-private partnership
initiative between pharmaceutical industry (European Federation of
Pharmaceultical Industry and Associations, EFPIA) and the European
Commission (DG Research - health priority) resulting in the European
Technology Platform project “Innovative Medicines Initiative” (IMI). Its
architecture is based on the identification of the main bottlenecks to the
development of innovative treatments (predictive pharmacology and
toxicology, identification and validation of biomarkers, patients'
recruitment, risk evaluation, and cooperation with the regulatory
authorities).
Simultaneously, initiatives both at the national and regional levels also
foster PPP in the therapeutic field. Regional competitivity clusters acting
in the biomedical sector, and national PPP calls such as the ANR (National
Research Agency) RIB (Research and Innovation in Biotechnology) call are
incentives for PPP projects. These regional and national PPP levels help
public and private partners to further build consortia able to compete for
EU-level calls, thus acting as incubators for EU PPP projects.
In spite of incentives and of the regional and national structuring of PPP,
weaknesses in the French system are linked to its fragmentation – multiple
transfer agencies, multiple research organisations (operator or funding
agency) – making contracts more difficult. This requires a simplified
organisation, with a single referent per area (health, technology...).
Improvement may also result from adaptation in the carreer, recruitment and
mobility, from support to scientists in the management of projects, and from
consistent support (without maintaining them artificially alive) to emerging
companies from concept through clinical development.
Pathways have been proposed to improve the efficiency of clinical research
in France and Europe, involving the public hospital sector, and this
requires the connection of disease-oriented networks and integrated
infrastructures in Europe. As stated in the IMI strategic research agenda on
efficacy, the quality of public infrastructures in Europe will be a key
factor for its competitiveness and attractiveness for both academic and
industry projects
Modèles de partenariats Public-Privé en France et en Europe
No full textLa table ronde intitulée "Modèles de Partenariats
Public-Privé en Europe, Comparaison France-pays européens"
réunissait des représentants du secteur académique et
industriel, de programmes scientifiques nationaux ou européens dans le
domaine de la Santé, d'acteurs régionaux et nationaux du partenariat
public-privé et des biotechnologies, et bien entendu de
représentants d'institutions ou de programmes Européens ou
extraeuropéens dans le domaine de le recherche en Santé, avec pour
objectifs :
le partage d'une vision sur les besoins, attentes et enjeux du Partenariat Public-Privé,
à partir de l'analyse de cas concrets et originaux, ou d'initiatives nouvelles de partenariats Public-Privé,
en tirer des enseignements – Facteurs clefs du succès,
identifier des axes de progrès - Recommandations.
L'actualité dans ce secteur est actuellement dominée par une
initiative de partenariat public-privé à l'échelle de l'Union
européenne entre l'industrie du médicament (EFPIA) et la Commission
européenne (DG Recherche – Sciences de la Vie), sous la forme du projet
de Plate-forme technologique Européenne "Innovative Medicines
Initiative" (IMI), dont l'architecture repose sur l'identification des
principaux obstacles au développement de médicaments innovants
(pharmacologie et toxicologie prédictives, identification et validation
des biomarqueurs, recrutement de patients, évaluation du risque et
coopération avec les instances réglementaires).
Simultanément, un certain nombre d'initiatives à l'échelle
nationale ou régionale viennent complémenter le maillage
géographique du partenariat : la constitution de pôles de
compétitivité à l'échelle régionale, ou l'appel d'offres
du réseau Innovation Biotechnologie (RIB) de l'ANR sont autant
d'incitations au partenariat public-privé, capables de structurer des
consortia aptes à répondre secondairement à des appels d'offres
de plus grande envergure à l'échelle européenne, réalisant
un escalier du partenariat.
En dépit de mesures incitatives et de cadres régionaux et nationaux
du partenariat, les difficultés décrites au niveau national reposent
en partie sur la multiplicité des acteurs – multiples agences de
valorisation, multiples organismes de recherche (opérateur ou agence de
moyens) qui peuvent compliquer la passation de contrats – rendant
souhaitable une structuration plus lisible avec un référent unique
par domaine (santé, technologie, etc.). Ces partenariats seront aussi
facilités par un travail concernant les statuts, le recrutement et la
mobilité, par un support aux scientifiques dans le pilotage des projets,
et par un soutien permettant d'accompagner (sans les maintenir
artificiellement en vie) des entreprises émergentes depuis le concept
jusqu'au stade du développement clinique.
Concernant le développement clinique, des pistes ont été
avancées quant à l'organisation de la recherche clinique en France
et en Europe, nécessairement structurée au sein du secteur public,
et supposant un couplage entre infrastructures intégrées à
l'échelle de l'Europe et réseaux thématiques. Comme le souligne
le volet "Efficacité" d'IMI, la qualité des infrastructures
publiques européennes sera un élément clé de sa
compétitivité et de son attractivité pour le secteur
académique comme industriel
Conditional coupling of striatal dopamine D1 receptor to transcription factors: ontogenic and regional differences in CREB activation
No full textp73 gene transcripts in human brain tumors: overexpression and altered splicing in ependymomas
No full text
Going Beyond Counting First Authors in Author Co-citation Analysis
Get PDFThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Variations on the Author
Get PDF“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
- …
